Lei Guo
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Research Biologist
Also affiliated: Qingdao University (2010–2024); Brigham and Women's Hospital (2000–2008); United States Food and Drug Administration (2005–2025); Kyushu University (1995–2000); Harvard University (2000–2008); North China University of Science and Technology (2024); Qingdao Agricultural University (2025); Shandong University (2025); University of Alberta (2002–2008); Harbin Medical University (2014); Duke University (2021); Canadian Institutes of Health Research (2001–2004); Baylor College of Medicine (2021); GTx (United States) (2002); Oita University (1998); Chinese Academy of Medical Sciences & Peking Union Medical College (2023); Peking University (2022–2024); Ningxia University (2024); Fudan University (2018); Biochemical Society (2010–2025); Tianjin Medical University General Hospital (2015); Chinese PLA General Hospital (2019); Yale University (2008); Tokyo Metropolitan Institute of Medical Science (1994); Beijing Chest Hospital (2022); Maine Farmland Trust (2021); Peking University People's Hospital (2022–2024); Duke Medical Center (2021); University of Kansas Medical Center (2021); The Affiliated Yongchuan Hospital of Chongqing Medical University (2004–2013); BioScience Laboratories (United States) (2008); Food and Drug Administration (2008–2025); Duke University Hospital (2021); Bureau of Geology and Mineral Exploration and Development of Guizhou Province (2022); First Affiliated Hospital of Harbin Medical University (2014); Hangzhou Medical College (2005); Northeast Forestry University (2025); Shandong Agricultural University (2022); The University of Tokyo (1999–2000); Zhejiang University (2005); Columbia University (2025); The University of Texas Southwestern Medical Center (2025); Chongqing Medical University (2004–2013)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Lei Guo's research focuses on understanding the metabolic and toxicological effects of various compounds, particularly in liver cells and animal models. Guo has investigated the role of cytochrome P450 enzymes, such as CYP1A1, CYP1A2, CYP3A4, CYP3A5, and CYP2C8, in drug metabolism and the development of cellular resistance to cytotoxic agents. This work includes the development and characterization of HepG2 cells overexpressing these enzymes to assess chemical-induced liver toxicity. Additionally, Guo's research has explored the effects of cannabidiol (CBD) and its metabolites on human Sertoli cells, examining transcriptomic changes, cellular senescence, and potential liver toxicity.
Metrics
- h-index: 52
- Publications: 203
- Citations: 18,086
Selected Publications
-
Corrigendum to “Characterizing the metabolites of the tyrosine-kinase inhibitor pexidartinib in mouse feces, urine, plasma, and liver” [J. Pharm. Biomed. Anal. 265 (2025) 117034] (2026)
-
Translating in vitro mechanistic findings to in vivo toxicity outcomes: A case study of Usnic acid hepatotoxicity (2026)
-
Potential anticancer effects and toxicity of flavones luteolin and apigenin <i>in vivo</i> (2025)
-
Characterizing the metabolites of the tyrosine-kinase inhibitor pexidartinib in mouse feces, urine, plasma, and liver (2025)
-
7-Hydroxycannabidiol and 7-carboxycannabidiol induced cytotoxicity via apoptosis and endoplasmic reticulum stress in human hepatic cells (2025)
-
Comparing the cannabidiol-induced transcriptomic profiles in human and mouse Sertoli cells (2025)
-
Investigation of cannabidiol-induced cytotoxicity in human hepatic cells (2024)
-
Metabolism and liver toxicity of cannabidiol (2024)
-
Hepatotoxicity of usnic acid and underlying mechanisms (2024)
-
Toxicity of cannabidiol and its metabolites in TM3 mouse Leydig cells: a comparison with primary human Leydig cells (2024)
-
CYP3A Mediates an Unusual C(sp<sup>2</sup>)−C(sp<sup>3</sup>) Bond Cleavage via <i>Ipso</i>‐Addition of Oxygen in Drug Metabolism (2024)
-
CYP3A Mediates an Unusual C(sp<sup>2</sup>)−C(sp<sup>3</sup>) Bond Cleavage via <i>Ipso</i>‐Addition of Oxygen in Drug Metabolism (2024)
-
Use of Lentivirus‐Based Method for Establishing TK6 Human Cell Lines Expressing Cytochrome P450 and its Applications in Genotoxicity Testing (2024)
-
Evaluation of weak genotoxicity of hydroxychloroquine in human TK6 cells (2024)
-
Induction of apoptosis by cannabidiol and its main metabolites in human Leydig cells (2023)
Collaboration Network
Top Collaborators
- The genotoxicity potential of luteolin is enhanced by CYP1A1 and CYP1A2 in human lymphoblastoid TK6 cells
- Characterization of cytochrome P450s (CYP)-overexpressing HepG2 cells for assessing drug and chemical-induced liver toxicity
- Roles of CYP3A4, CYP3A5 and CYP2C8 drug-metabolizing enzymes in cellular cytostatic resistance
- In vitro effects of cannabidiol and its main metabolites in mouse and human Sertoli cells
- Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells
Showing 5 of 16 shared publications
- In vitro effects of cannabidiol and its main metabolites in mouse and human Sertoli cells
- Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells
- Metabolism and liver toxicity of cannabidiol
- Induction of apoptosis by cannabidiol and its main metabolites in human Leydig cells
- The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib
Showing 5 of 11 shared publications
- Metabolism of a Selective Serotonin and Norepinephrine Reuptake Inhibitor Duloxetine in Liver Microsomes and Mice
- The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib
- Study of the roles of cytochrome P450 (CYPs) in the metabolism and cytotoxicity of perhexiline
- Identifying the Reactive Metabolites of Tyrosine Kinase Inhibitor Pexidartinib In Vitro Using LC–MS-Based Metabolomic Approaches
- CYP3A Mediates an Unusual C(sp<sup>2</sup>)−C(sp<sup>3</sup>) Bond Cleavage via <i>Ipso</i>‐Addition of Oxygen in Drug Metabolism
Showing 5 of 8 shared publications
- Characterization of cytochrome P450s (CYP)-overexpressing HepG2 cells for assessing drug and chemical-induced liver toxicity
- Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells
- Induction of apoptosis by cannabidiol and its main metabolites in human Leydig cells
- The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib
- Toxicity of cannabidiol and its metabolites in TM3 mouse Leydig cells: a comparison with primary human Leydig cells
Showing 5 of 7 shared publications
- The genotoxicity potential of luteolin is enhanced by CYP1A1 and CYP1A2 in human lymphoblastoid TK6 cells
- Characterization of cytochrome P450s (CYP)-overexpressing HepG2 cells for assessing drug and chemical-induced liver toxicity
- The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib
- The expression of Phase II drug-metabolizing enzymes in human B-lymphoblastoid TK6 cells
- Evaluation of weak genotoxicity of hydroxychloroquine in human TK6 cells
Showing 5 of 7 shared publications
- Metabolism of a Selective Serotonin and Norepinephrine Reuptake Inhibitor Duloxetine in Liver Microsomes and Mice
- The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib
- Study of the roles of cytochrome P450 (CYPs) in the metabolism and cytotoxicity of perhexiline
- Identifying the Reactive Metabolites of Tyrosine Kinase Inhibitor Pexidartinib In Vitro Using LC–MS-Based Metabolomic Approaches
- CYP3A Mediates an Unusual C(sp<sup>2</sup>)−C(sp<sup>3</sup>) Bond Cleavage via <i>Ipso</i>‐Addition of Oxygen in Drug Metabolism
Showing 5 of 7 shared publications
- Characterization of cytochrome P450s (CYP)-overexpressing HepG2 cells for assessing drug and chemical-induced liver toxicity
- In vitro effects of cannabidiol and its main metabolites in mouse and human Sertoli cells
- Metabolism and liver toxicity of cannabidiol
- Toxicity of cannabidiol and its metabolites in TM3 mouse Leydig cells: a comparison with primary human Leydig cells
- Use of Lentivirus‐Based Method for Establishing TK6 Human Cell Lines Expressing Cytochrome P450 and its Applications in Genotoxicity Testing
Showing 5 of 6 shared publications
- Metabolism of a Selective Serotonin and Norepinephrine Reuptake Inhibitor Duloxetine in Liver Microsomes and Mice
- Identifying the Reactive Metabolites of Tyrosine Kinase Inhibitor Pexidartinib In Vitro Using LC–MS-Based Metabolomic Approaches
- CYP3A Mediates an Unusual C(sp<sup>2</sup>)−C(sp<sup>3</sup>) Bond Cleavage via <i>Ipso</i>‐Addition of Oxygen in Drug Metabolism
- CYP3A Mediates an Unusual C(sp<sup>2</sup>)−C(sp<sup>3</sup>) Bond Cleavage via <i>Ipso</i>‐Addition of Oxygen in Drug Metabolism
- CYP3A Mediated Metabolism of Tyrosine Kinase Inhibitor Pexidartinib and Alleviated its Cytotoxicity to HepG2 Cells
Showing 5 of 6 shared publications
- In vitro effects of cannabidiol and its main metabolites in mouse and human Sertoli cells
- Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells
- Induction of apoptosis by cannabidiol and its main metabolites in human Leydig cells
- Toxicity of cannabidiol and its metabolites in TM3 mouse Leydig cells: a comparison with primary human Leydig cells
- Comparing the cannabidiol-induced transcriptomic profiles in human and mouse Sertoli cells
Showing 5 of 6 shared publications
- Metabolism of a Selective Serotonin and Norepinephrine Reuptake Inhibitor Duloxetine in Liver Microsomes and Mice
- Identifying the Reactive Metabolites of Tyrosine Kinase Inhibitor Pexidartinib In Vitro Using LC–MS-Based Metabolomic Approaches
- CYP3A Mediates an Unusual C(sp<sup>2</sup>)−C(sp<sup>3</sup>) Bond Cleavage via <i>Ipso</i>‐Addition of Oxygen in Drug Metabolism
- CYP3A Mediates an Unusual C(sp<sup>2</sup>)−C(sp<sup>3</sup>) Bond Cleavage via <i>Ipso</i>‐Addition of Oxygen in Drug Metabolism
- CYP3A Mediated Metabolism of Tyrosine Kinase Inhibitor Pexidartinib and Alleviated its Cytotoxicity to HepG2 Cells
- In vitro effects of cannabidiol and its main metabolites in mouse and human Sertoli cells
- Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells
- Induction of apoptosis by cannabidiol and its main metabolites in human Leydig cells
- Toxicity of cannabidiol and its metabolites in TM3 mouse Leydig cells: a comparison with primary human Leydig cells
- Comparing the cannabidiol-induced transcriptomic profiles in human and mouse Sertoli cells
- Metabolism and liver toxicity of cannabidiol
- Comparing the cannabidiol-induced transcriptomic profiles in human and mouse Sertoli cells
- Use of Lentivirus‐Based Method for Establishing TK6 Human Cell Lines Expressing Cytochrome P450 and its Applications in Genotoxicity Testing
- Potential anticancer effects and toxicity of flavones luteolin and apigenin <i>in vivo</i>
- Characterization of cytochrome P450s (CYP)-overexpressing HepG2 cells for assessing drug and chemical-induced liver toxicity
- Metabolism and liver toxicity of cannabidiol
- 7-Hydroxycannabidiol and 7-carboxycannabidiol induced cytotoxicity via apoptosis and endoplasmic reticulum stress in human hepatic cells
- Characterization of cytochrome P450s (CYP)-overexpressing HepG2 cells for assessing drug and chemical-induced liver toxicity
- Study of the roles of cytochrome P450 (CYPs) in the metabolism and cytotoxicity of perhexiline
- Hepatotoxicity of usnic acid and underlying mechanisms
- The genotoxicity potential of luteolin is enhanced by CYP1A1 and CYP1A2 in human lymphoblastoid TK6 cells
- In vitro effects of cannabidiol and its main metabolites in mouse and human Sertoli cells
- 7-Hydroxycannabidiol and 7-carboxycannabidiol induced cytotoxicity via apoptosis and endoplasmic reticulum stress in human hepatic cells
Similar Researchers
Based on overlapping research topics